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A B S T R A C T
Purpose: To investigate response to sequential treatment schedules and risk of development of refractory
epilepsy in childhood.
Methods: All children younger than 14 years with two or more unprovoked seizures seen at our hospital
between 1994 and 2004 were included and prospectively followed. ‘‘Seizure control’’ was deﬁned as a 2-
year seizure-free interval without further recurrences except those related to attempts of medication
withdrawal and ‘‘refractory epilepsy’’ as failure of >2 drugs plus >1 seizure/month for 18 months.
Results: 343 Patients were included, 191 males and 152 females. Mean age at diagnosis was 4y 10 mo
(SD 3 year 10 month). Mean follow-up period was 76.2 mo (SD 35.2). The probability of achieving
‘‘seizure control’’ was 70% and 86% at 5 and 10 years. 59% of patients were ‘‘controlled’’ with the ﬁrst drug
used. Among patients failing the ﬁrst, second and third therapeutic regimen due to lack of efﬁcacy, 39%,
23% and 12% respectively were ﬁnally ‘‘controlled’’ with subsequent treatment schedules Risk of
development of refractory epilepsy was 8% and 12% at 6 and 10 years.
Conclusion: After failing a ﬁrst drug, a signiﬁcant proportion of children can still be controlled with
subsequent therapeutic schedules. Only a small proportion develops refractory epilepsy.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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journal homepage: www.e lsev ier .com/ locate /yse izKnowing how epilepsy responds to antiepileptic drugs (AEDs) is
important in decision making and in providing information for
patients and/or their parents. Most patients with epilepsy do well
on antiepileptic treatment. However, a proportion of patients
ranging between 6% and 41% in different studies, do not respond
adequately to AED and develop refractory (intractable) epilepsy.1–6
At least in part, this variability could reﬂect the use of different
deﬁnitions of refractory epilepsy. On the other hand, it is known
that failure of the ﬁrst AED used diminishes the probability of
response to subsequent AEDs. In a study with adolescents and
adults, only 21% of patients in whom the ﬁrst drug failed due to
lack of efﬁcacy were controlled with subsequent therapeutic
schedules.5,6 Other studies in children suggest a higher probability
of success.1,2 These are important and unsatisfactorily answered
questions. Consequently, the main objectives of the present work
have been to study response of childhood epilepsy to sequential
treatment schedules and risk for the development of refractory
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1.1. Deﬁnitions and classiﬁcation criteria
Seizures were considered unprovoked when they occurred
without any known proximate precipitant. Epilepsywas deﬁned as
occurrence of two or more unprovoked seizures at least 24 h apart.
Epilepsies were classiﬁed according to their etiology as idiopathic,
cryptogenic or remote symptomatic, following the ILAE criteria.7 In
particular, epilepsies were classiﬁed as remote symptomatic when
they occurred in a patient with a history of a neurological deﬁcit of
pre or perinatal origin or a prior neurological insult such as CNS
infection, stroke or signiﬁcant head trauma.7 Therefore, this group
included patients with global developmental delay/mental retar-
dation and cerebral palsy. Classiﬁcation of patients by epilepsy
syndrome was also performed according to the ILAE revised 1989
classiﬁcation.8 Classiﬁcations were performed with data available
at 6 months after diagnosis. ‘‘Initial remission’’ was deﬁned as a
seizure-free period of x years, with or without further recurrences
until the end of the study period. ‘‘Terminal remission’’ was deﬁned
as a seizure-free interval of x years without further recurrences.
Consequently, the difference between ‘‘initial’’ and ‘‘terminal’’
remission is that in the ﬁrst case the patient may be or not in
remission at the end of the study period whereas in the second, the
patient is always in remission. In this study we examined 1 and 2-
year initial remission and 1-year terminal remission. ‘‘Seizurevier Ltd. All rights reserved.
J. Ramos-Lizana et al. / Seizure 18 (2009) 620–624 621control’’ was deﬁned as a seizure-free period of 2 years without
further recurrences except those related to attempts of medication
withdrawal. We considered as recurrences related to attempts of
medication withdrawal, those occurring after the onset of
medication withdrawal and not repeated after reinitiating anti-
epileptic medication. A patient was considered ‘‘controlled’’ with
antiepileptic drugs if he/she attained a 2-year seizure-free period
without further relapses and also if he/she attained a 2-year
seizure-free period, had a seizure after medication withdrawal,
reinitiated medication and did not have more seizures until the
end of the study period. In other words, ‘‘seizure control’’ is like a
terminal remission, but seizures related to drugwithdrawal are not
taken into account because they can not be attributed to drug
failure. Untreated patients were considered ‘‘controlled’’ when
they reached a 2-year seizure-free period without further relapses.
As can be noted, the operational deﬁnition of ‘‘controlled’’ in this
study includes seizure-free patients both on and off medication.
We considered ‘‘treatment failures’’ those changes of medica-
tion due to persistence of seizures at maximum tolerated doses.
Drugs withdrawn due to intolerable adverse effects in patients
without seizures were not included as ‘‘treatment failures’’ for the
purposes of this study’’.
We deﬁned refractory epilepsy as failure, due to lack of seizure
control, of more than 2 AEDwith an average of more than 1 seizure
per month for 18 months and no more than three consecutive
months seizure-free during this interval (deﬁnition A).3,4We chose
this deﬁnition as themain deﬁnition because it is suitable for using
in a survival analysis. To compare it with previously published
studies we used three other deﬁnitions. Deﬁnition B: terminal
remission <1 year and longest remission <3 months during the
last year of observation despite the optimal use of at least two AED,
either alone or in combination.2 Deﬁnition C: failure of three or
more AED andmore than one seizure permonth during the ﬁnal 12
months of follow-up.1 Deﬁnition D: failure to achieve a 1-year
terminal remission.5,6 Different criteria were retrospectively
applied using the prospectively collected data about frequency
of seizures.
1.2. Cohort selection
Torreca´rdenas Hospital is the reference hospital of the province
of Almerı´a (Spain). The only EEG laboratory and pediatric
neurology division in the province are located in this Hospital.
Between June 1st, 1994 and December 31st, 2004 all patients
younger than 14 years of age seen consecutively at our hospital due
to two or more newly-diagnosed unprovoked seizures at least 24 h
apart were enrolled in a prospective study. Patients with seizures
limited to neonatal period, inborn errors of metabolism, neuro-
degenerative disorders, children already on antiepileptic treat-
ment and those who had been examined previously in other
centres were excluded. Consequently, all patients were directly
referred by primary care pediatricians or were ﬁrst seen in the
emergency department of our hospital.
Informed consent to participate in the study was obtained and
the study was approved by the ethical committee of the Hospital.
1.3. Initial evaluation
For every patient, family and medical history were taken, a
physical and neurological examination was performed and a
standard EEG was obtained at diagnosis of epilepsy. When the
standard EEG was normal, a sleep record was performed. EEG
records were read by independent neurophysiologists.
Computed tomography or magnetic resonance imaging was
performed at least in the cases with abnormal ﬁndings in the
neurological examination, partial seizures, focal abnormalities onthe EEG (except in the case of benign childhood epilepsy with
centro-temporal spikes) or West syndrome.
Since this was an observational study, the treating physician
chose the AED to be used. Some patients were not treated.
1.4. Follow-up
All patients were followed by personal interviews, at least at 6
to 12 months intervals, until December 31st, 2006 (to allow for a
minimum of 2 year follow-up) or until they attained a remission of
3 years without AED (i.e 3 years with neither treatment nor
relapses). Patients in remission were thereafter contacted by
telephone until a follow-up of 5 years without antiepileptic
treatment was completed. After that, patients were instructed to
contact us if a relapse occurred. Otherwise patients were
considered in remission. We did so to simplify the follow-up
process, because previous studies showed that recurrence risk >5
years after medication withdrawal is very low.
Patients failing treatment due to lack of efﬁcacy either had the
original drug substituted or were offered combination therapy. In
general, medicationwithdrawalwas attempted after a seizure-free
period of 2 years. In case of relapse, the same drug was reinitiated.
Mean follow-up period was 76.2 (SD 35.2) months (range 24 to
139). Out of 343 children, 249 (73%) were followed for more than 4
years, 168 (49 %) formore than 6 years and 104 (30%) formore than
8 years. 66 patients achieved a 5-years remission period without
antiepileptic treatment. Only one of these patients contacted us
afterwards due to a relapse. This happened 85 months after
treatment withdrawal.
1.5. Analysis
The probabilities of achieving a 1-year initial remission, a 2-
years initial remission, a 1-year terminal remission and the risk of
developing refractory epilepsy (Deﬁnition A)were calculated using
Kaplan–Meier survival curves. Patients entered the study on the
date of diagnosis of epilepsy. Probability of response to different
treatment schedules was calculated as percentages. For latter
analysis only treatments initiated before December 31st, 2004
were taken into account, to allow for a minimum of 2 years of
follow-up. Calculations were performed by means of SPSS for
Windows, version 15.0, statistical software.
2. Results
2.1. General features of the sample
Three hundred and ﬁfty three children were enrolled in the
study. Eight patients were lost to follow-up before completing a
minimum follow-up period of 2 years and 2 children died within 2
years of diagnosis. This left 343 patients whowere followed-up for
more than 2 years and constituted the sample of this study.
Thereafter, another six patients were lost to follow-up and four
children died. Overall, we lost contact with only 4% (8+6) cases of
the initial sample. Mean age at diagnosis was 4 years and 10
months (SD 3 years and 10 months). 68 (20%) of the children were
younger than 1 year of age at diagnosis of epilepsy, 236 (69%) were
between 1 and 9 years and 39 (11%) were 10 years of age or older.
191 were male and 152 female. A neuroimaging study was carried
out in 291 (85%) patients: computed tomography was carried out
in 105, magnetic resonance imaging in 113 and both in 72 patients.
Etiology was remote symptomatic in 111 (32%) cases, cryptogenic
in 86 (25%) and idiopathic in 146 (43%). Details of speciﬁc aetiology
in remote symptomatic cases are shown in Table 1.
Thirty four (10%) patients were not treated (17 benign
childhood epilepsies with centrotemporal spikes, two early-onset
Table 1
Speciﬁc aetiologies of remote symptomatic cases (n = 111) with ﬁndings in neuroimaging studies.
Aetiology n Neuroimaging ﬁndings n
Neurocutaneous disordersa 6 Typical ﬁndings 6
Brain malformationsb 15 Speciﬁc ﬁndings 15
Chromosomal abnormalities 4 Ventricular enlargement plus cortical atrophy 3
Normal 1
Monogenic mendelian diseasesc 5 Normal 5




Unilateral lateral ventricle enlargement
2
Postnatal acquired lesionsd 9 Destructive lesions 9
Unspeciﬁc global developmental delay/intellectual disabilitye 39 Normal 39
Others 8 Various ﬁndings 7
Normal 1
a Tuberous sclerosis: 5; Sturge-Weber syndrome: 1.
b Holoprosencephaly: 1; schizencephaly: 1; hemimegalencephaly: 1; corpus callosum agenesis: 2; periventricular heterotopia: 2; polymicrogyrias: 2; pachygyria: 1;
lissencephaly: 1; hydrocephalus: 1; focal cortical displasia: 1; hydranencephaly: 1; arachnoid cyst: 1.
c Rett syndrome: 2; Angelman syndromes: 3.
d CNS tumours: 4; head traumatisms: 4; bacterial meningitis: 1.
e With normal MRI, no motor disability and no deﬁnite cause.
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epilepsies with infrequent generalized tonic-clonic seizures, eight
cryptogenic localization-related epilepsies, one symptomatic
localization-related epilepsy and three epilepsies without unequi-
vocal partial or generalized seizures).
2.2. Overall probability of remission
For the overall sample (n = 343), at the end of the study period,
308 (90%) patients had achieved a 1-year initial remission, 271
(79%) a 2-year initial remission, 247 (72%) ‘‘seizure control’’ and
260 (76%) a 1-year terminal remission. For treated patients
(n = 309) these ﬁgures were 275 (89%), 238 (77%), 216 (70%) and
229 (74%), respectively. For untreated patients (n = 34) these
ﬁgures were 33 (97%), 33 (97%), 31 (91%) and 31 (91%),
respectively.
Chi squared test showed that the following factors were
signiﬁcantly more frequent in treated than in untreated patients:
age at onset of epilepsy <1 year (p = 0.037), remote symptomatic
aetiology (p = 0.001), presence of global developmental delay or
mental retardation (p = 0.007), abnormal neuroimaging
(p = 0.005), a multiple ﬁrst seizure (p = 0.000) and more than ﬁve
seizures before diagnosis (p = 0.000). On the other hand, an
idiopathic aetiology was more frequent in untreated patients
(p = 0.010). There were no signiﬁcant differences between both
groups in sex, presence ofmotor deﬁcit, presence of various seizureTable 2
Kaplan–Meier estimates of the probability of achieving a 1-year initial remission (1y.
probability of developing refractory epilepsy (Deﬁnition A). Overall sample (n = 343). 9
Years of follow-up
1 2 3 4
1y.IR% 50 74 83 87
(95% CI) (45, 55) (69, 79) (79, 87) (83, 91)
Number at risk 172 91 50 34
2y.IR% 44 64 76
(95% CI) (39, 49) (61, 69) (71, 81)
Number at risk 192 106 60
Control% 39 55 65
(95% CI) (34, 44) (50, 60) (60, 70)
Number at risk 209 136 91
Refractory epilepsy% 5% – 7%
(95%CI) (3, 7) (4, 10)
Number at risk 325 239types, number of seizures during the ﬁrst 6months after diagnosis,
ﬁrst seizure as status or a history of prior febrile convulsions or
neonatal convulsions.
At the end of the study period, 205 out of the overall sample
(60%) and 202 out of 247 ‘‘controlled’’ patients (82%) were without
antiepileptic treatment.
The probability of achieving a 1-year initial remission, a 2-year
initial remission and ‘‘seizure control’’ in the overall sample
(n = 343), calculated by Kaplan–Meier curves is shown in Table 2.
2.3. Response to antiepileptic treatment
Three hundred and nine patients were treated. The ﬁrst AED
used was valproic acid in 186 cases, carbamazepine in 64,
oxcarbazepine in 18, phenobarbital in 15, phenytoin in 2,
ethosuximide in 4, vigabatrin in 7, lamotrigine in 1 and topiramate
in 1, in all cases in monotherapy. In 11 patients diagnosed as West
syndrome, the ﬁrst schedule consisted in oral corticosteroids or
ACTH plus valproic acid. The second schedule was a monotherapy
in 50 patients and a polytherapy with two drugs in 35. The third
schedule was monotherapy in 13 children, polytherapy with two
drugs in 27 and polytherapy with more than two drugs in 4. The
fourth and subsequent schedules consisted in monotherapy in 2
patients, polytherapy with two drugs in 14 and polytherapy with
more than two drugs in 10. 27 out of 518 drug treatments (5.2%)
had to be suspended due to unacceptable adverse effects.IR), a 2-year initial remission (2y.IR) and ‘‘seizure control’’ and of the cumulative
5% CI: 95% conﬁdence interval.
5 6 7 8 9 10
91 92 93 94 95 95
(88, 94) (89, 95) (90, 96) (91, 97) (92, 98) (94, 98)
22 15 9 8 6 4
81 85 87 88 89 90
(76, 86) (81, 90) (83, 92) (84, 93) (84, 94) (86, 95)
39 26 16 15 10 8
70 75 78 81 83 86
(65, 75) (70, 80) (73, 83) (76, 86) (78, 88) (80, 92)
64 45 31 22 18 10
– 8% – 11% – 12%
(5, 11) (7, 15) (7, 17)
197 103 64
Table 3
Response to subsequent treatment schedules. (A) Number of patients. (B) Number of patients responding to each schedule/overall sample (n = 309), % (95% CI). (C) Number of
patients responding to each schedule/total number of patients treated with this schedule, % (95% CI). 1y.TR: 1-year terminal remission. 95% CI: 95% conﬁdence interval.
1st schedule n = 309 2nd schedule n = 85 3rd schedule n = 44 4 th schedule n = 26
A 1y.TR 188 26 10 4
Seizure control 183 23 7 3
B 1y.TR 61% (56, 66) 8% (5, 11) 3% (2, 4) 1% (0, 3)
Seizure control 59% (54, 65) 7% (4, 10) 2% (1, 3) 1% (0, 3)
C 1y.TR 61% (56, 66) 30% (20, 40) 23% (10, 35) 15% (6, 33)
Seizure control 59% (54, 65) 27% (17, 36) 16% (5, 26) 12% (10, 23)
Table 4
Probability of ﬁnally achieving a 1-year terminal remission (1y.TR) and ‘‘seizure
control’’ with subsequent treatment schedules after failing a regimen due to lack of
efﬁcacy. Calculated as number of patients responding to subsequent schedules/
number of patients trying subsequent schedules. (a) Number of patients trying




n (%) (95% CI)
Failure of ﬁrst Schedule (n = 85)a 40 (47 %) (36, 58) 33 (39 %) (29, 49)
Failure of second schedule (n = 44)a 14 (32 %) (18, 46) 10 (23 %) (11, 35)
Failure of third Schedule (n = 26)a 4 (15 %) (1, 29) 3 (12 %) (3, 23)
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treatment schedule (A), the proportion of patients responding to
each treatment schedule in relation to total number of treated
patients (B) and the proportion of patients responding to each
treatment schedule in relation to the number of patients treated
with this schedule (C). For example, 23 out of the 309 treated
patients (7%) were controlled with the second schedule and 23 out
of the 85 patients treated with a second schedule (27%) were
controlled with this regimen. From another point of view, Table 4
shows the probability of response to subsequent regimens in
patients failing treatment because of lack of efﬁcacy. For example,
126 patients were not controlledwith the ﬁrst treatment schedule.
In 85 cases therewas enough time until the end of the study period
to try at least one more regimen. 33 out of these 85 children (39%)
were ﬁnally ‘‘controlled’’.
2.4. Refractory epilepsy
Table 5 shows the proportions of patients meeting the different
deﬁnitions of refractory epilepsy in our study and the proportions
observed in the original studies using these criteria.
The cumulative probability of meeting the Deﬁnition A of
refractory epilepsy, calculated by Kaplan–Meier curves, is shown
in Table 3. 16 (53%) of the patients who fulﬁlled criteria of
refractory epilepsy did so before 24 months, 18 (60%) before 36
months and 24 (80%) before 48 months from the diagnosis. Four
cases (13%) met the criteria of refractory epilepsy after a period of
remission of at least 2 years. On the other hand, two patients (7%),
achieved a period of remission of at least 2 years after having met
the Deﬁnition A for refractory epilepsy.Table 5
Proportion of patients meeting the different deﬁnitions of refractory epilepsy
compared with proportion obtained in the original studies where these deﬁnitions
were used.
Refractory epilepsy Our study n (%) Prior studies (reference)
Deﬁnition A 30 (8.7%) 13.8 % (4)
Deﬁnition B 30 (8.7%) 6 % (2)
Deﬁnition C 30 (8.7%) 8.4 % (1)
Deﬁnition D 83 (24.2%) 40.7 % (6)3. Discussion
The main limitation of this study is that it is hospital-based.
Nevertheless, it has been designed to obtain a sample as
representative of general population as possible. In Spain, primary
care pediatricians do not treat children with epilepsy. There are
three hospitals in the province of Almerı´a. Torreca´rdenas Hospital
is the reference hospital and it has the only EEG laboratory and
pediatric neurology division in the province. Consequently, most
patients in the province with epileptic seizures are cared for in
Torreca´rdenas Hospital. However, some patients are seen in the
other two hospitals due to decision of their parents or primary care
physician. In this case, difﬁcult-to-treat patients are referred to our
hospital. To avoid a selection bias, patients previously examined in
other centres were excluded. There is no other institution in the
province that treats patients with epilepsy. Therefore, our sample
is based exclusively on direct referrals by primary care pediatri-
cians and patients ﬁrst seen at the emergency department of our
hospital. In addition, features of our sample are in accordance with
those found in population-based incidence cohort studies and
other prospective cohort studies usually considered reasonably
representative of the general population.9–12
Patterns of recurrence and remission of seizures in epilepsy
depend on the speciﬁc policies about medication withdrawal in
each centre. Usually, in discussion with parents, we propose
stopping medication in patients who are seizure-free for 2 years.
For this reason, we have chosen the achievement of a period of 2
years without seizures and without further relapses except those
related to attempts of medication withdrawal (‘‘seizure control’’),
as the main measure of patient’s response to AED. Other authors
have used a 1-year terminal remission: a seizure-free interval of at
least one year at the end of the study period. In our study, the
probability of achieving ‘‘seizure control’’ was only slightly lower
than the probability of attaining a 1-year terminal remission.
However, we consider that the variable ‘‘seizure control’’ gives a
more precise notion of the efﬁcacy of antiepileptic medication. For
example, it is more informative to say that 72% of patients achieve
a seizure-free period of 2 years and do not have more seizures or
only have seizures related to attempts of medication withdrawal,
than to say that 76% have been seizure-free for more than one year
at the end of the study period (both results observed in our series).
The present study shows an excellent outcome in childhood
epilepsy. The probability of achieving a 2-year initial remission
was 81% and 90% at 5 and 10 years, respectively. Some studies,13,14
including a large population-based one15 and two studies dealing
exclusively with children16,17 have found similar results (prob-
ability of achieving a 2-year remission in the range of 81–90% at 5–
9 years). Moreover, seizures were ‘‘controlled’’ in 70% of patients at
5 years and in 86% at 10 years. 60% of the overall sample and 82% of
the ‘‘controlled’’ patients were without antiepileptic treatment at
the end of the study period. In addition, 10% of our patients were
not treated at all.
As expected, a previous study showed that the probability of
response to subsequent therapeutic regimens after failure of a ﬁrst
J. Ramos-Lizana et al. / Seizure 18 (2009) 620–624624AED is higher if the ﬁrst treatment failed because of adverse effects
than if it failed due to lack of efﬁcacy.5 We have chosen to focus on
treatment failure due to lack of efﬁcacy.
In our study, the probability of achieving ‘‘seizure control’’ was
59% with the ﬁrst treatment schedule, 27% with the second, 16%
with the third and 12% with the fourth and subsequent (number of
patients controlled with a treatment schedule/number of patients
treated with this schedule). From another point of view, among
patients who failed the ﬁrst treatment schedule because of lack of
efﬁcacy, 39%were ‘‘controlled’’ with subsequent schedules. Among
thosewho did not respond to the second schedule, 23%were ﬁnally
‘‘controlled’’. Among children who did not respond to the third,
12% were ﬁnally ‘‘controlled’’. The probability of success of
subsequent treatment schedules is considerably better in our
study than in the recently updated hospital-based study with
adolescents and adults by Mohanraj and Brodie.5,6 In this study,
21% of the patients in whom a ﬁrst treatment schedule failed
because of lack of efﬁcacy ﬁnally achieved a 1-year terminal
remission (47% in our study), 8% of the patients who did not
respond to a second schedule attained a 1-year terminal remission
(32% in our series) and 4% of patients in whom a third schedule
failed ﬁnally entered 1-year terminal remission (15% in our
sample). Our results are in line with another study in patients less
than 16 years old.2 Although this work was not speciﬁcally
designed to investigate the response to sequential therapeutic
regimens, the authors report that 58% of patients, who did not
attain a 1-year terminal remission with the ﬁrst drug used, ﬁnally
did it with subsequent therapeutic schedules. Another study in
children younger than 16 years old also suggested a more
favourable outcome.1 It must be noted that overall outcome is
also better in our study than in the study by Mohanraj and Brodie.
In the latter study only 59% of patients achieved a 1-year terminal
remission compared with 76% in our study.
In our series, 8.7% of the patients met our criteria for refractory
epilepsy. Deﬁnitions of refractory epilepsy vary in different
studies. Those studies in children using stringent criteria, similar
to those used in our study, have found refractory epilepsy in 6% to
14% of the cases.1–4 When applying the different deﬁnitions of
refractory epilepsy used in these studies, we have found the same
proportion of refractory epilepsy. The different ﬁgures in these
studies do not appear to be related to the criteria used but probably
are due to different sample features and follow-up duration. A
recent population-based study in adults using stringent criteria
has shown a rate of refractory epilepsy of 16%.18 With a broad
deﬁnition (failure to reach a 1-year terminal remission), the
proportion of intractable cases raises in our series to 24%. This
ﬁgure is similar to that found in one of the previously cited cohort
of children19 but lower than the 41% observed in the study by
Mohanraj and Brodie with adolescents and adults.6 Another study
in children with a broad deﬁnition (no 5-year remission ever
during a follow-up of at least 10 years) found a rate of refractory
epilepsy of 19%.20 This latter deﬁnition was not tested in our study
because a more prolonged follow-up is needed.
Nineteen per cent of our patients could not be ‘‘controlled’’ with
antiepileptic drugs but did not fulﬁl our intractability criteria. This
is an intermediate group that includes both patients with
occasional seizures and patients with frequent seizures. A
signiﬁcant proportion of these patients would be labelled by
other authors as refractory.
If we deﬁned refractory epilepsy as the failure of two or more
drugs with an average of more than one seizure per month for 18
months and no more than 3-months seizure free during this
interval,3 refractoriness becomes a dynamic process. In our study,
the risk of having developed refractory epilepsy increased withtime from 5.2% at 2 years to 12.1% at 10 years. 40% of refractory
patients met the criteria for refractoriness after 3 years from
diagnosis. Moreover, in 13% of the cases, intractability developed
after a period of remission of at least 2 years. On the other hand,
6.6% of patients that met intractability criteria achieved thereafter
a period of remission of at least 2 years. The same ﬁnding was
observed in the original study using this deﬁnition3,4 where
refractory epilepsy criteria were met after 3 years in 32% of the
cases and 13% of the patients who met intractability criteria were
in remission when last contacted.
In conclusion, most childhood epilepsies can be controlled with
AED, more than half with the ﬁrst drug used. Among those patients
that do not respond to the ﬁrst drug, a signiﬁcant proportion can
still be controlled with subsequent therapeutic schedules. Only a
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